Comparison Of ER-Positive Versus ER-Negative In Breast Cancer Women And Invasive Ductal Carcinoma In The West Of Iran: A Direct Correlation With Vascular Invasion.

Background & Objective: ER expression is the main indicator of potential responses to endocrine therapy, and approximately 70% of human breast cancers are hormone-dependent and ER-positive. The aim of the study is to evaluate the correlation between risk factors with ER status in breast cancer patients in the West of Iran. Methodology: In a retrospective study, 260 breast cancer women were included invasive ductal carcinoma our Clinic. A sufficient sample size was selected from any patient, and the slides were stained by hematoxylin and eosin (H & E) method. Estrogen receptor (ER) and progesterone receptor (PR) positivity were defined as ≥10% positive tumor cells with nuclear staining. Chi-square test and T-test were used to analyze the significance of correlation between the expression of ER and other parameters. Results: The patients were divided into two groups (156 patients with ER-positive group and 104 patients with ER-negative group). There was a significant difference between histological grade, nuclear grade, lymph node metastasis, tumor size and vascular invasion and also tumor markers of HER2, PR, P53 expression with ER status. Based on binary logistic regression analysis, in patients with ER-positive, more patients had vascular invasion and PR-positive, but P53 was negative. Conclusion: There was a direct correlation between vascular invasion and PR, with ER status and a reverse correlation between p53 with ER status.

Non-hematological Adverse Events of Imatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

The aim of this study is survey of effects of Imatinib with dose 400 mg per day after 6 months in the patients with CML chronic phase. Between of 2010 - 2014, fifty four patients with high risk CML referred to Taleghani hospital in Kermanshah, Iran. We used the questionnaire about adverse events (AEs) of Imatinib capsule (Cipla manufacture, India) in these patients. For grading AEs, We used Common Terminology Criteria for AEs (CTCAE) manuscript (low AE equals grade 1, 2: high AE equals 3, 4 and grade 5 is optional) that diagram related to them was plotted with Excel 2007 software. 54 patients that referred to hospital, 27 patients were female and 27 patients were male. Mean of age for the patients was 45.7 ± 13.8 years (range, 23 to 78 years). Fatigue, (66.7%), myalgia (61.6%), joint pain (61.6%) and cramp (57.4%) are the most AEs in the patients after treatment of Imatinib. In the future studies we should evaluate non-hematological AEs for Imatinib in a lot of CML patients and apply to CTCAE manuscript exactly.